HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Now? US Cosmetic Review Has Evaluated Up To 91% Of Ingredients Used Nationwide

Executive Summary

CIR’s work is far from done, says executive director Bart Heldreth, citing the cosmetics industry's vibrant innovation tradition and ingredient re-review needs that should keep the program sufficiently busy.

You may also be interested in...



CIR Expert Panel Wraps Five Ingredient Safety Assessments, Finalizes 2022 Priorities

Meeting virtually on 13-14 September, Cosmetic Ingredient Review's independent expert panel issued final safety assessments for red algae, tea tree and three other ingredients/groups, as well as eight tentative reports and five insufficient data announcements. The group also finalized its review priorities for 2022.

US Cosmetics Modernization Bill Relaunched, Now With Fragrance Allergen Labeling, PFAS Ban

The Personal Care Products Safety Act was reintroduced in the US Senate on 17 June with industry support including leading brands at big-name multinationals. The latest “Feinstein bill” for modernizing US cosmetics regulations purports to strengthen counterfeit product protections while floating additional requirements for fragrance allergen labeling and banning intentionally added PFAS.

Cosmetic Ingredient Innovation In An Increasingly Cruelty-Free World; Is It Possible?

Visibility is low into the availability of new cosmetic ingredients since 2013, but there does appear to be a viable pathway for innovations to reach the EU market, despite the animal testing ban, as well as California, where similar prohibitions will go into effect in 2020. Still, industry’s best bet is to continue investing in alternative methods development and promoting their acceptance with regulators.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel